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Interleukin (IL)-27, a heterodimeric cytokine, has been reported to be involved in the 
pathogenesis of autoimmune diseases through mediating differentiation of Th1 or Th17 cells and 
immune cell activity or survival. However, the origin and effects of IL-27 in joints of rheumatoid 
arthritis (RA) remain unclear. In this study, we investigated the distribution and 
anti-inflammatory roles of IL-27 in RA synovium. The IL-27 levels in plasma of RA patients, 
osteoarthritis (OA) patients, or healthy volunteers (n = 15 per group) were equivalent and were at 
most 1 ng/ml, but the IL-27 level in synovial fluid of RA patients (n=15, mean 0.13 ng/ml; range 
0.017–0.37 ng/ml) was significantly higher than that in synovial fluid of OA patients (n = 15, 
mean 0.003 ng/ml; range 0–0.033 ng/ml) and potentially lower than in plasma. We analyzed the 
protein level of IL-27 produced by RA fibroblast-like synoviocytes (FLSs) or mononuclear cells 
(MNCs) from RA or OA synovial fluid or peripheral blood and showed that IL-27 in RA joints 
was derived from MNCs but not from FLSs. We also found by flow cytometry that 
IL-27-producing MNCs were CD14
+




 cells were clearly detected in 
RA synovium but rarely in OA synovium by immunohistochemistry. Furthermore, we 
demonstrated that a relatively physiological concentration of IL-27 below 10 ng/ml suppressed 
the production of IL-6 and CCL20 from RA FLSs induced by proinflammatory cytokines 
through the IL-27/IL-27R axis. In the synovial fluid of RA, the IL-27 level interestingly had 
positive correlation with the IFN- level (r=0.56, p=0.03), but weak negative correlation with 
the IL-17A level (r = −0.30, p = 0.27), implying that IL-27 in inflammatory joints of RA induces 
Th1 differentiation and suppresses the development or the migration of Th17 cells. These 
findings indicate that circulating IL-27-producing CD14
+
 cells significantly infiltrate into 
inflamed regions such as RA synovium and have anti-inflammatory effects in several ways: both 
directly through the reduction of IL-6 production, and possibly through the induction of Th1 
development and the suppression of Th17 development; and indirectly by regulation of 
recruitment of CCR6
+
 cells, such as Th17 cells, through the suppression of CCL20 production. 
Our results suggest that such a serial negative feedback system could be applied to RA therapy. 
Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, manifesting as 
systemic inflammatory arthritis with hypertrophy of the synovium followed by the destruction of 
cartilage, bone and joint structures. Several in vivo experimental autoimmune animal models and 
in vitro human studies have suggested that interleukin (IL)-17-secreting helper T (Th17) cells can 
be considered a critical mediator of RA with respect to tissue inflammation or bone resorption 
[1–4]. Th17 cells specifically express chemokine receptor CCR6, and its ligand CCL20 recruits 
Th17 cells [1, 5]. An association of the dinucleotide polymorphism of the CCR6 gene 
(CCR6DNP) with RA susceptibility has been suggested [6]. 
IL-27 is a recently identified cytokine, which is structurally related to IL-12 as a 
heterodimeric cytokine, similar to IL-23 and IL-35. IL-27 is composed of Epstein–Barr 
virus-induced gene 3 (EBI3), a p40-related molecule, and IL-27p28, a p35-related molecule [7]. 
IL-27 is produced by antigen presenting cells (APCs) including dendritic cells (DCs) and 
monocytes, and is secreted as a heterodimer [8]. IL-27 is reported to be expressed at chronic 
inflammatory sites, such as synovial tissues in RA [9], skin lesions in psoriasis [10], inflamed 
intestine in Crohn’s disease, and granulomas in tuberculosis or sarcoidosis [11]. IL-27 suppresses 
the development of Th17 cells and the production of cytokines including IL-17A from activated 
CD4
+
 T cells by blocking RAR-related orphan receptor C (RORC) expression in humans and in 
several experimental animal models, while it induces Th1 differentiation [9, 12–15]. 
IL-27 receptor (IL-27R) is also a heterodimer of WSX-1 (IL-27R), a homologue of 
IL-12R2, and gp130, a component of the IL-6 receptor [16, 17]. Both components are 
coexpresssed in various human cell types, including monocytes, DCs, T cells, B cells, natural 
killer cells, mast cells and endothelial cells, and both components are required for the signal 
transduction of IL-27 [17]. Downstream of IL-27R, mainly STAT1 and STAT3 are activated [17, 
18]. 
In a murine collagen-induced arthritis (CIA) model, administration of IL-27 reduces the 
amount of serum IL-6, cellular infiltration to the joints, synovial hyperplasia and joint erosion at 
the onset of the disease [9]. IL-27 also inhibits human receptor of NF-B ligand 
(RANKL)-mediated osteoclastogenesis [19, 20]. These reports suggest protective roles for IL-27 
in the pathogenesis of arthritis. In contrast, it is also reported that IL-27 possesses pathogenic 
roles in RA. In experimental animal models of adjuvant-induced arthritis and 
proteoglycan-induced arthritis, IL-27 is critically involved with the development of arthritis by 
inducing the differentiation of naïve T cells into interferon (IFN)--producing Th1 cells [21, 22]. 
In humans, high concentrations of IL-27 induce the production of IL-6 and inflammatory 
chemokines from FLSs of established RA [23]. These conflicting reports reflect the complex 
functions of IL-27 in human immunology. 
In this study, we investigated the source and role of IL-27 in RA. We show that 
IL-27-producing CD14
+
 cells significantly infiltrate RA synovium, and that physiological 
concentrations of IL-27 could have anti-inflammatory effects in several ways: both directly 
through the suppression of IL-6 production and possibly through Th1 differentiation; and 
indirectly by regulating recruitment of CCR6
+
 cells including Th17 cells through the suppression 
of CCL20 production. Our results suggest that IL-27 might be a potential therapeutic agent for 
RA. 
2. Material and methods 
2.1. Cytokines and reagents 
Human recombinant tumor necrosis factor (TNF)-, human recombinant IL-1, human 
recombinant IL-6, human recombinant soluble IL-6 receptor (sIL-6R), and human recombinant 
IL-17A were purchased from PeproTech USA (Rocky Hill, NJ, USA). The following reagents 
were purchased from R&D Systems (Minneapolis, MN, USA): human recombinant IL-27, 
anti-human TCCR/WSX-1 antibody, isotype control IgG, human TCCR/WSX-1 Fc chimera, 
human IgG1 Fc, anti-human IL-27 antibody and isotype control IgG. Anti-human CD8a antibody, 
anti-human CD4 antibody, anti-human CD19 antibody and anti-human CD14 antibody were 
purchased from eBioscience (San Diego, CA, USA). 
 
2.2. Ethics approval 
Ethics approval for this study was granted by the ethics committee of Kyoto University 
Graduate School and Faculty of Medicine, and written consent was obtained for every sample. 
Informed consent was obtained from 69 participants (28 with RA, 26 with knee osteoarthritis 
(OA), and 15 as healthy volunteers (HV)). The clinical features of participants in this study are 
summarized in Table 1. RA and OA were diagnosed according to the criteria of the American 
College of Rheumatology.   
  
2.3. Preparation of peripheral blood and synovial fluid samples 
Peripheral blood samples were collected in ethylenediaminetetraacetic acid dipotassium 
salt (EDTA-2K)-containing tubes to separate the plasma. After both peripheral blood and 
synovial fluid samples were centrifuged at 400  g for 7 min, the supernatants were stored at –20 
C until analysis. 
 
2.4. Isolation of mononuclear cells (MNCs) 
After centrifugation of peripheral blood and synovial fluid samples, the pellets were 
suspended in RPMI-1640 (Sigma-Aldrich, St Louis, MO, USA) with 1% fetal bovine serum 
(FBS; ICN, Aurora, OH, USA). Debris was removed from the synovial fluid samples with a 70 
m cell strainer (BD Biosciences, Basel, Switzerland). Each sample was layered on the same 
amount of Histopaque-1077 (Sigma-Aldrich). After centrifugation at 400  g for 30 min at room 
temperature, MNCs were collected and washed twice with PBS. 
 
2.5. MNC culture 
Isolated MNCs were suspended in RPMI-1640 with 1% FBS, and 1  106 MNCs were 
stimulated with 20 ng/ml phorbol myristate acetate (PMA, Sigma-Aldrich) and 1 M ionomycin 
(Sigma-Aldrich) in 24-well ultralow cluster plates (Costar, New York, USA). After 4 h 
incubation at 37 C in a humidified 5% CO2 atmosphere, the medium with suspended MNCs was 
collected and centrifuged at 400  g. Supernatants and MNCs were used separately for analysis. 
 
2.6. Fibroblast-like synoviocyte (FLS) culture 
Human synovial tissues were obtained during total knee replacement surgery in Kyoto 
University Hospital from RA patients fulfilling the revised criteria of the American College of 
Rheumatology. FLSs of RA patients were prepared as previously reported [5]. Briefly, the tissues 
were minced into small pieces and digested with 2 mg/ml collagenase (Wako, Osaka, Japan) in 
Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich) containing 100 U/ml penicillin 
and 100 g/ml streptomycin at 37 C for 2 h, followed by digestion with 0.05% trypsin and 
0.02% ethylenediaminetetraacetic acid (EDTA) at 37 C for 30 min. The cells were cultured in 
DMEM containing 10% FBS in 100 mm dishes (Iwaki, Tokyo, Japan) at 37 C in a humidified 
5% CO2 atmosphere. After 3–7 passages, FLSs were plated in 12-well plates (Corning, NY, 
USA) in DMEM containing 10% FBS. At confluence, FLSs were washed twice with 
phosphate-buffered saline (PBS) and stimulated with various concentrations of cytokines in 
serum-free DMEM for 48 h, and the supernatant or the cell layer was then collected for further 
analyses. 
2.7.Measurement of cytokines and chemokines 
The concentration of human TNF-, IL-1, IL-6, IL-17A and IFN- was measured by 
ELISA (eBioscience), with detection limits of 1.55 pg/ml, 1.37 pg/ml, 1.61 pg/ml, 3.64 pg/ml 
and 1.18 pg/ml respectively. The concentration of human CCL20 was measured by ELISA (R&D 
Systems), with a detection limit of 0.17 pg/ml. The concentration of IL-27 was measured by 
ELISA (Biolegend, San Diego, CA, USA), with a detection limit of 11 pg/ml. 
 
2.8 . Immunohistochemical staining 
FLSs that were seeded in Lab-Tek chamber slides (Nalge Nunc International, Rochester, 
NY, USA) were fixed in 4% paraformaldehyde. RA synovium was fixed in 4% 
paraformaldehyde, embedded in paraffin and then sectioned and dewaxed. The endogenous 
peroxidase activity in both sample types was blocked with 0.6% hydrogen peroxide in methanol 
for 30 min. Anti-WSX-1 antibody (10 g/ml) was applied, and the sections were incubated for 
30 min at room temperature. The equivalent normal goat IgG was used as a negative control. The 
reaction products were visualized using Vectastain ABC Kit and DAB Peroxidase Substrate Kit 
(both from Vector Laboratories, Burlingame, CA, USA) according to the manufacturer’s 
instructions. The sections were counterstained with hematoxylin for 2 min. 
 2.9. Flow cytometry 
Isolated MNCs were suspended in RPMI-1640 with 10% FBS, and 1  106 MNCs were 
stimulated with 20 ng/ml PMA (Sigma-Aldrich), 1 M ionomycin (Sigma-Aldrich) and 0.67 
l/ml GolgiStop (BD Biosciences) in 24-well ultralow attachment plates (Costar). After 4 h 
incubation at 37 C in a humidified 5% CO2 atmosphere, MNCs were stained for CD4, CD8, 




2.10. Confocal microscopy 
Detection of CD14 and intracellular IL-27 present in the frozen sections of synovium 
tissues from RA or OA patients was performed using a laser confocal microscope (AZ-C1; Nikon, 
Tokyo, Japan). Briefly, a piece of fresh synovium from RA or OA patients was embedded in 
Tissue-Tek O.C.T. compound (Sakura Finetechnical Co. Ltd., Tokyo, Japan) and frozen in liquid 
nitrogen. This frozen block, stored at –80 C until usage, was cut 10–40 m thick in the Leica 
CM1850 cryostat (Leica Microsystems, Wetzler, Germany) and mounted on Superfrost-plus 
slides. After fixation with 4% paraformaldehyde and blocking with 10% normal serum, the 
frozen sections were stained with directly conjugated antibodies. 
 
2.11. Statistical analysis 
Student’s t-test was used for statistical analyses unless indicated otherwise. P < 0.05 was 
considered significant. The correlation of IL-27 with IFN-or IL-17A was evaluated by Pearson 
product-moment correlation coefficient. 
3. Results 
3.1. IL-27 is expressed similarly in plasma of RA and OA patients and HV, but is significantly 
higher in RA synovial fluid than in OA synovial fluid 
To investigate the possible contribution of IL-27 to the pathogenesis of RA, we measured 
the concentration of IL-27 in the synovial fluid from patients with RA or OA, and in plasma from 
HV or patients with RA or OA. The IL-27 level in synovial fluid of RA patients (mean 0.13 
ng/ml; range 0.017–0.37 ng/ml) was significantly higher (P < 0.0005) than that in OA patients 
(mean 0.003 ng/ml; range 0–0.033 ng/ml) (Fig. 1). However, the concentrations of plasma IL-27 
in RA patients (mean 0.45 ng/ml; range 0.17–0.86 ng/ml), OA patients (mean 0.34 ng/ml; range 
0.017–0.83 ng/ml) and HV (mean 0.48 ng/ml; range 0.09–1.0 ng/ml) were similar (Fig. 1). These 
results imply that the joint environment by nature contains little IL-27 compared with the 
peripheral circulation, and that immunological inflammation of synovial tissue may contribute to 
the production of IL-27 in joints. 
 
3.2. IL-27 in RA synovial fluid originates not from RA FLSs but from MNCs 
To investigate the source of IL-27 in the synovial fluid of RA patients, we investigated the 
production of IL-27 by RA FLSs. RA FLSs stimulated with proinflammatory cytokines such as 
TNF-, IL-1, IL-6 or IL-17A failed to produce detectable IL-27 (Fig. 2A). We then evaluated 
the production of IL-27 by MNCs to investigate other origins of IL-27. Stimulated MNCs from 
synovial fluid and peripheral blood produced IL-27 protein (Fig. 2B). Interestingly, the 
production of IL-27 by MNCs in RA synovial fluid was significantly lower than that by MNCs 
from peripheral blood from RA and OA patients (Fig. 2B), as observed in figure 1. These results 




 cells produce IL-27 and infiltrate RA synovium 
To determine the IL-27-secreting population in MNCs, we conducted intracellular staining 
of MNCs followed by flow cytometry. We stained MNCs with anti-CD4, -CD8, -CD14, or 
-CD19, and intracellular anti-IL-27. Only CD14
+
 cells were IL-27 positive (Fig. 3A). 
Immunohistochemistry showed that IL-27-producing CD14
+
 cells were present in RA synovium 
but rarely in OA (Fig. 3B). These results indicate that IL-27 in RA synovial fluid originates from 
CD14
+
 cells infiltrating synovial tissue and synovial fluid. 
 
3.4. IL-27R is expressed on RA FLSs and is ubiquitously distributed in RA synovium 
Next, we investigated the distribution of IL-27R on RA synovial cells using 
immunohistochemical staining. IL-27R is a heterodimer composed of WSX-1 (IL-27R) and 
gp130. Because gp130 is known to be expressed on RA synovial cells [24], we investigated the 
expression of WSX-1 on RA FLSs and RA synovium. WSX-1 was expressed on RA FLSs and 
was ubiquitously distributed in RA synovium (Fig. 4A-D). These results indicate that FLS and 
most cell populations of synovium are under the control of IL-27 and that IL-27 might have 
widespread influence on the pathogenesis of RA. 
 
3.5. IL-27 suppresses the production of IL-6 or CCL20 induced by stimulation of RA FLSs with 
proinflammatory cytokines 
To investigate the influence of IL-27 on RA FLSs, we measured the production of 
proinflammatory cytokines by RA FLSs in the presence or absence of IL-27. Because the 
concentration of IL-27 in plasma or synovial fluid in RA was at most 1 ng/ml (Fig. 1), we used 
IL-27 at a maximum concentration of 10 ng/ml. IL-27 alone failed to induce TNF-, IL-1, or 
IL-6 (Fig. 5A). However, IL-27 significantly suppressed the IL-6 production induced by TNF- 
or IL-17A from FLSs (Fig. 5B). IL-27 also significantly suppressed the CCL20 production 
induced by TNF- (Fig. 5C). These results suggest that IL-27 plays anti-inflammatory roles in 
two ways: both directly via the suppression of IL-6 production and indirectly by regulating 
recruitment of CCR6
+
 cells including Th17 cells, via the suppression of CCL20 production. 
Furthermore, the addition of decoy WSX-1 to these experiments significantly abrogated the 
suppression of IL-6 production induced by TNF- from FLSs (Fig. 5D). These results indicate 
that stimulation of IL-27R with IL-27 has a suppressive effect on the production of 
proinflammatory cytokines. 
 
3.6. IL-27 has positive correlation with IFN- but weak negative correlation with IL-17A in the 
synovial fluid of RA.  
IL-27 is known to induce Th1 development and suppress Th17 development [9, 12-15] and 
reduced the production of CCL20 (Fig. 5C). To evaluate the possible regulation in the 
development and the migration of Th cells by IL-27 in inflamed joints of RA, we measured the 
concentration of IFN- and IL-17A in the synovial fluid of RA analyzed in figure 1. The 
concentrations of IFN- and IL-17A were 0.026 ng/ml on the average ranging from 0.004 ng/ml 
to 0.057 ng/ml, and 0.052 ng/ml ranging from 0 ng/ml to 0.21 ng/ml, respectively. The IL-27 
level had significant positive correlation with the IFN- level (r=0.56, p=0.03), but weak 
negative correlation with the IL-17A level (r = −0.30, p = 0.27) (Fig. 6). These results indicate 
that IL-27 in the inflamed joints of RA has effect in the increase of IFN- producing cells and 
reduction of IL-17A producing cells, implying induction of Th1 differentiation and suppression 
in the differentiation or the migration of Th17 cells by IL-27. 
Discussion 
In this study, we showed that the concentration of IL-27 in plasma of RA and OA patients 
and HV was at most 1 ng/ml, while that in synovial fluid of RA and OA was at most 400 pg/ml 
and 40 pg/ml, respectively (Fig. 1). Recently, IL-27 at 10–100 ng/ml was reported to activate RA 
FLSs as an inflammatory cytokine [23]. In our laboratory, a high concentration (100 ng/ml) of 
IL-27 tended to induce IL-6 production from RA FLSs. However, based on the detected 
concentration of IL-27 in plasma or synovial fluid, we considered that a concentration of less 
than 10 ng/ml better reflects physiological conditions than a concentration of 10–100 ng/ml. 
Experimental autoimmune animal models or in vitro human studies suggest that Th17 cells 
play a crucial role in RA [1–4]. Indeed, clinical treatment for RA targeting IL-17A has shown 
significant effects [25]. Th17 cells specifically express the chemokine receptor CCR6, and its 
ligand CCL20 recruits Th17 cells into sites of inflammation [1, 5]. IL-27 has been reported to 
suppress the development of Th17 cells and the production of cytokines including IL-17A from 
CD4
+
 T cells by blocking RORC expression in humans and in several experimental animal 
models, whereas it induces Th1 differentiation [9, 12–15]. In our experiment of RA synovial 
fluid, the IL-27 level had significant correlation with the IFN- level but weak negative 
correlation with the IL-17A level (Fig. 6). Although IFN- and IL-17A can be produced by other 
cells than Th cells, these results implies that IL-27 in the inflamed joints of RA also induced Th1 
development and suppress the development or the migration of Th17 cells. 
IL-27 also suppresses the production of CCL20 induced by TNF- from human 
keratinocytes [10]. In our experiment with FLSs, IL-27 suppressed the production of CCL20 
induced by TNF- and the production of IL-6 induced by TNF- or IL-17A. These data 
collectively indicate that in RA, IL-27 suppresses not only the proinflammatory cytokine 
network but also the recruitment of CCR6
+
 cells including Th17 cells. 
IL-27R is a heterodimeric receptor consisting of WSX-1 and gp130. gp130 is known to be 
expressed on RA synovial cells and although IL-27 binds to WSX-1, signal transduction in 
response to IL-27 is never seen without the combination of both components [7, 17, 24]. 
Therefore, the addition of decoy WSX-1 successfully neutralized the suppressive effect of IL-27 
in our experiments (Fig. 5D). WSX-1 is expressed on FLSs, and is also ubiquitously distributed 
on RA synovium (Fig. 4A, C). These results indicate that IL-27 might have a widespread 
suppressive effect on the synovium in RA. 
We have shown that CD14
+
 cells infiltrate RA synovium produce IL-27 (Fig. 3B). DCs as 




 cells, because 
human circulating CD14
+
 monocytes have the capacity to differentiate into macrophages or DCs 
after immigration into extravascular tissues [26]. In particular, it was reported that human 
monocyte-derived DCs transdifferentiate into osteoclasts in the RA microenvironment, and that 
in the intermediate stage of the transdifferentiation they express CD14 and function as APCs 
[27]. 
From these results, we suggest that IL-27-producing CD14
+
 cells might be circulating in 
peripheral vessels irrespective of RA or OA, but that these cells rarely migrate to normal 
synovium or synovial fluid. This may be why the concentration of IL-27 in joints was lower. 
IL-27-producing CD14
+
 cells might preferentially infiltrate the synovium in RA joints and 
contribute to modification of joint inflammation. Notably, the sequence of anti-inflammatory 




 cells infiltrating into RA synovium is one of the 
negative feedback systems acting against synovial inflammation in RA. Because IL-27 also 
suppresses the development of Th17 cells [9, 12–15], IL-27 is considered to protect joints from 
inflammation induced by Th17 cells. However, the IL-27 level in RA synovial fluid was lower 
than in RA peripheral blood (Fig. 1). This lower IL-27 level in RA joints might result in 
incomplete regulation of Th17 cells in RA joints and contribute to the severity and perpetuation 
of joint inflammation. This may be partly because the poor regional blood flow in joints causes 




 cells compared with the peripheral circulation. Alternatively, 
the cytokine environment of the joint might affect the production of IL-27 by CD14
+
 cells. In this 
respect, reinforcement of the suppressive function of IL-27 might be a novel therapeutic agent 






 cells specifically infiltrate the synovium after the onset of RA, 
and IL-27 plays anti-inflammatory roles in RA. IL-27 inhibited not only the production of IL-6 
from RA FLSs but also the recruitment of CCR6
+
 cells including Th17 cells into RA joints by 
suppressing the production of CCL20 from RA FLS. This sequence is regarded as one of the 
negative feedback systems against inflammation in RA. 
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Figure legends 
 
Fig. 1. The concentration of IL-27 in plasma or synovial fluid of RA or OA patients. 
The concentrations of IL-27 in plasma of RA (RAPB) patients, OA (OAPB) patients and healthy 
volunteers (HVPB) (n = 15 per group) or synovial fluid of RA (RASF) and OA (OASF) patients 
were measured by ELISA. Vertical bars represent the means ± SD. Significant differences 
between RASF and RAPB are indicated by ***P < 0.0005.  
 
Fig. 2. MNCs but not FLSs produce IL-27. 
(A) RA FLSs were incubated for 48 h with vehicle or the indicated cytokine at a concentration of 
2 or 10 ng/ml and the concentration of IL-27 in the triplicate supernatants was measured by 
ELISA. Recombinant IL-6 was added together with 100 ng/ml sIL-6R, because FLSs express 
little membranous IL-6R. (B) The concentrations of IL-27 in the culture supernatants of MNCs 
from peripheral blood of RA (RAPB, n=26) and OA (OAPB, n=17) patients and synovial fluid of 
RA (RASF, n=16) patients were measured by ELISA. Vertical bars represent the means ± SD. 




 cells in MNCs and synovium produce IL-27. 
(A) Following PMA/ionomycin and GolgiStop stimulation, MNCs of healthy volunteers were 
stained with antibodies to the indicated surface antigens and IL-27 and analyzed by flow 
cytometry. The results represent three independent experiments. (B) RA or OA synovial 
synovium was stained with anti-CD14 (red) and IL-27 (green) antibodies and observed by 




 cells are depicted as yellow. The upper left 
or right panel is the image of RA synovium with anti-CD14 or anti-IL-27 antibodies, respectively. 
The lower left or right panel is the image of RA synovium or OA synovium, stained with 
anti-CD14 and anti-IL-27 antibodies, respectively. Representative staining of each group is 
shown. 
 
Fig. 4. WSX-1 is ubiquitously expressed on RA FLSs or synovium. 
The expression of WSX-1 was analyzed by immunohistochemical staining of RA FLSs (A, B) 
and RA synovium (C, D). The left panels (A, C) show WSX-1 staining, and the right panels (B, 
D) show staining with isotype-matched control IgG. Representative staining of each group is 
shown. 
 
Fig. 5. IL-27 suppresses the production of IL-6 and CCL20 from RA FLSs via WSX-1. 
(A) FLSs of RA were incubated for 48 h with IL-27 at the indicated concentration and the 
concentrations of TNF-, IL-1 or IL-6 in the triplicate supernatants were measured by 
ELISA. (B) FLSs of RA were incubated for 48 h with 2 ng/ml TNF- or IL-17A in 
combination with IL-27 at the indicated concentration, and the IL-6 level in the triplicate 
supernatants was measured by ELISA. (C) FLSs of RA were incubated for 48 h with 10 
ng/ml TNF- in combination with IL-27 at the indicated concentration, and the CCL20 level 
in the quadruplicate supernatants was measured by ELISA. (D) FLSs of RA were incubated 
for 48 h with 2 ng/ml TNF- in the presence or absence of 2 ng/ml IL-27 in combination 
with 10 g/ml IgG control or 10 g/ml WSX-1 Fc chimera and the IL-6 level in the 
quadruplicate supernatants was measured by ELISA. Vertical bars represent the means ± SD. 
Significant differences compared with samples without the addition of IL-27 are indicated by 
*P < 0.05. N.D. not detectable. 
 
Fig. 6. The correlation of IL-27 with IFN- or IL-17A in the synovial fluid of RA. 
The concentrations of IFN- or IL-17A in the synovial fluid of RA patients analyzed in figure 1 
were measured by ELISA (n=15). Pearson product-moment correlations of the IL-27 level with 
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RA: rheumatoid arthritis, OA: osteoarthritis, HV: healthy volunteers, ESR: erythrocyte sedimentation rate, CRP: C-
reactive protein, MMP-3: metalloproteinase-3,  DAS28: 28-joint Disease Activity Score, NA: not applicable 
Table 1: Clinical features of the participants  
Characteristics RA OA  HV 
Number of participants 28 26 15 
Sex, male/female 7/21 3/23 7/8 
Age, mean (range) 59.2 (22 to 80) 74.7 (60 to 85) 43.9 (32 to 58) 
Duration of RA (year), mean (range) 11.8 (0.5 to 46) NA NA 
ESR (mm/hr), mean (range) 48.1 (4 to 119) NA NA 
CRP (mg/dl), mean (range) 2.69 (0.0 to 9.6) NA NA 
MMP3 (ng/ml), mean (range) 320 (87.1 to 800) NA NA 
DAS28, mean (range) 4.43 (2.23 to 7.13) NA NA 
Kellgren/Lawrence grade, n NA Ⅰ :0,  Ⅱ :4,  Ⅲ :12,  Ⅳ :10 NA 
Medication, n (%)   
    Predonisolone 20 (71%) NA NA 
    Methotrexate 18 (67%) NA NA 
    Infliximab 2 (7.1%) NA NA 
    Eternercept 2 (7.1%) NA NA 
    Tocilizumab 2 (7.1%) NA NA 
    Tacrolimus 4 (14%) NA NA 
    Salazosulfapyridine 6 (21%) NA NA 
    Bucillamine 3 (11%) NA NA 
    Gold 1 (3.5%) NA NA 
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